Company A is the second largest pharmaceutical company in Japan and is known for research-based medicine. It spent $1.345 billion on research and development in 2008 through its 15 locations worldwide. Company B is the third largest in Japan, investing $1.64 billion in 2008 for its research pipeline to meet future healthcare needs. Both companies significantly invest in global research and development.